Form 4: Recursion Pharmaceuticals Director Receives Significant Equity Grant

Namandje Bumpus, a Director at Recursion Pharmaceuticals, Inc. (RXRX), was granted 11,008 restricted stock units and options to purchase 22,016 shares of Class A Common Stock as part of her compensation.

Summary

• On June 18, 2025, Namandje Bumpus, a Director of Recursion Pharmaceuticals, Inc., received a grant of 11,008 restricted stock units (RSUs) of Class A Common Stock.
• These RSUs were granted at a price of $0 and will vest on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, contingent on continued service.
• Following this transaction, Ms. Bumpus beneficially owns 47,557 shares of Class A Common Stock directly.
• Additionally, on the same date, Ms. Bumpus was granted stock options to acquire 22,016 shares of Class A Common Stock with an exercise price of $5.11 per share.
• These stock options will vest and become exercisable on the earlier of June 18, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, also subject to her continued service.
• The stock options have an expiration date of June 18, 2035.
• Following this grant, Ms. Bumpus beneficially owns 22,016 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The document reports a standard equity compensation grant to a director, which is a neutral to slightly positive event as it aligns director interests with shareholders. It does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with those of the shareholders, incentivizing long-term performance and value creation.
• The equity compensation is part of the Issuer's Outside Director Compensation Policy, indicating a structured and transparent approach to executive and director remuneration.

Future Outlook

The restricted stock units and stock options granted to the director are scheduled to vest on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, contingent upon the director's continued service to the company.

Industry Context

The grant of equity compensation, including restricted stock units and stock options, to directors is a common practice across various industries, particularly in the biotechnology and pharmaceutical sectors, to attract and retain talent and align leadership incentives with shareholder value.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and stock options as part of director compensation is a standard practice in the U.S. public company landscape, including the biotechnology and pharmaceutical industries.
• The vesting schedule, tied to continued service and future annual meetings, is typical for such grants, aiming to ensure long-term commitment from board members.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The restricted stock units and stock options will vest on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the reporting person's continued service.

Key Dates

Keywords

Recursion Pharmaceuticals, RXRX, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership